Business Description
Celcuity Inc
NAICS : 541714
SIC : 2834
ISIN : US15102K1007
Total Employee Number:
155Description
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.2 | |||||
Equity-to-Asset | 0.13 | |||||
Debt-to-Equity | 6.04 | |||||
Debt-to-EBITDA | -1.87 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -11.4 | |||||
3-Year EPS without NRI Growth Rate | -12.5 | |||||
3-Year FCF Growth Rate | -11.9 | |||||
3-Year Book Growth Rate | -30.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.86 | |||||
9-Day RSI | 57.11 | |||||
14-Day RSI | 48.24 | |||||
3-1 Month Momentum % | 16.94 | |||||
6-1 Month Momentum % | 31.31 | |||||
12-1 Month Momentum % | 1017.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.31 | |||||
Quick Ratio | 12.31 | |||||
Cash Ratio | 11.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.6 | |||||
Shareholder Yield % | -3.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -239.86 | |||||
ROA % | -54.97 | |||||
ROIC % | -7481.79 | |||||
3-Year ROIIC % | -1742.34 | |||||
ROC (Joel Greenblatt) % | -31923.9 | |||||
ROCE % | -55.2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 90.95 | |||||
Price-to-Tangible-Book | 90.95 | |||||
EV-to-EBIT | -28.12 | |||||
EV-to-EBITDA | -28.14 | |||||
EV-to-Forward-Revenue | 110.73 | |||||
EV-to-FCF | -28.09 | |||||
| Price-to-Net-Current-Asset-Value | 93.47 | |||||
| Price-to-Net-Cash | 160.24 | |||||
Earnings Yield (Greenblatt) % | -3.56 | |||||
FCF Yield % | -3.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CELC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celcuity Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.9 | ||
| Beta | 1.0288 | ||
| 3-Year Sharpe Ratio | 1.01 | ||
| 3-Year Sortino Ratio | 4.8 | ||
| Volatility % | 188.15 | ||
| 14-Day RSI | 48.24 | ||
| 14-Day ATR ($) | 7.061592 | ||
| 20-Day SMA ($) | 94.3625 | ||
| 12-1 Month Momentum % | 1017.9 | ||
| 52-Week Range ($) | 11.7 - 151.02 | ||
| Shares Outstanding (Mil) | 48.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celcuity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celcuity Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 137 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 47 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 46 days | ||
| Goldman Sachs 47th Annual Global Conference | 2026-06-10 08:00 | 92.59 (+5.43%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 13:25 | 88.95 (+2.65%) | ||
| Phase 3 VIKTORIA-1 PIK3CA Mutant Cohort Clinical Trial Results Conference Call | 2026-06-02 08:00 | 122.96 (-7.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 124.47 (+0.94%) | ||
| General meeting for 2026 | 2026-05-14 09:00 | 124.47 (+0.94%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 124.47 (+0.94%) |
Show
Entries
Celcuity Inc Frequently Asked Questions
What is Celcuity Inc(CELC)'s stock price today?
The current price of CELC is $100.95. The 52 week high of CELC is $151.02 and 52 week low is $11.70.
When is next earnings date of Celcuity Inc(CELC)?
The next earnings date of Celcuity Inc(CELC) is 2026-08-14 Est..
Does Celcuity Inc(CELC) pay dividends? If so, how much?
Celcuity Inc(CELC) does not pay dividend.
Guru Commentaries on NAS:CELC
No articles.
Press Release
Articles on Celcuity Inc
No articles.
Headlines
See More- 1
Jun 04, 2026
Celcuity raises $500M in upsized 0.25% convertible notes sale
Seeking Alpha • 4:56am
Jun 02, 2026
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations
Seeking Alpha • 9:10am
Celcuity falls after detailed late-stage trial data for breast cancer drug
Seeking Alpha • 9:02am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers